March 17, 2025 12:50 PM EDTUpdated 02:02 PM
R&D
Pharma

As­traZeneca re­ports Phase 3 suc­cess for rare dis­ease drug at heart of Amolyt deal

Ayisha Sharma

News Reporter

As­traZeneca’s $1.05 bil­lion bet on French biotech Amolyt Phar­ma seems to be pay­ing off.

On Mon­day, the UK drug­mak­er re­port­ed a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

TRENDING NOW

Trump’s HHS de­fends Biden-era stance on 340B re­bate mod­els

FDA staff re­turn to White Oak cam­pus en masse af­ter Trump ad­min­is­tra­tion push

In­cyte's stock sinks as piv­otal skin dis­ease da­ta dis­ap­point

Post-Hoc: Kennedy's an­ti-vac­cine ac­tions should­n't sur­prise any­one

As­traZeneca taps Al­teogen in deal worth more than $1.3B to make sub­cu­ta­neous can­cer drugs

Avid­i­ty seeks to 'set the stan­dard' as it heads to FDA with Duchenne drug

A service from the Financial Times